News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
820,225 Results
Type
Article (75802)
Company Profile (643)
Press Release (743780)
Multimedia
Podcasts (125)
Webinars (14)
Section
Business (228159)
Career Advice (3776)
Deals (39235)
Drug Delivery (129)
Drug Development (89360)
Employer Resources (198)
FDA (17869)
Job Trends (17122)
News (388481)
Policy (38831)
Tag
Academia (2999)
Academic (2)
Accelerated approval (6)
Adcomms (29)
Allergies (94)
Alliances (56187)
ALS (99)
Alzheimer's disease (1501)
Antibody-drug conjugate (ADC) (156)
Approvals (17835)
Artificial intelligence (302)
Autoimmune disease (28)
Automation (16)
Bankruptcy (402)
Best Places to Work (12632)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (440)
Bladder cancer (85)
Brain cancer (32)
Breast cancer (301)
Cancer (2429)
Cardiovascular disease (204)
Career advice (3217)
Career pathing (34)
CAR-T (173)
Cell therapy (485)
Cervical cancer (21)
Clinical research (72169)
Collaboration (910)
Compensation (552)
Complete response letters (30)
COVID-19 (2866)
CRISPR (48)
C-suite (265)
Cystic fibrosis (107)
Data (2267)
Decentralized trials (2)
Denatured (43)
Depression (55)
Diabetes (297)
Diagnostics (6915)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (135)
Drug pricing (126)
Drug shortages (33)
Duchenne muscular dystrophy (101)
Earnings (94245)
Editorial (44)
Employer branding (25)
Employer resources (167)
Events (129030)
Executive appointments (773)
FDA (19198)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (808)
Gene editing (119)
Generative AI (30)
Gene therapy (355)
GLP-1 (849)
Government (5128)
Grass and pollen (6)
Guidances (67)
Healthcare (20873)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (146)
Indications (30)
Infectious disease (3026)
Inflammatory bowel disease (153)
Inflation Reduction Act (11)
Influenza (56)
Intellectual property (101)
Interviews (741)
IPO (17717)
IRA (51)
Job creations (4978)
Job search strategy (2627)
Kidney cancer (11)
Labor market (42)
Layoffs (553)
Leadership (24)
Legal (9929)
Liver cancer (81)
Lung cancer (345)
Lymphoma (159)
Machine learning (7)
Management (65)
Manufacturing (345)
MASH (75)
Medical device (14619)
Medtech (14624)
Mergers & acquisitions (22061)
Metabolic disorders (786)
Multiple sclerosis (87)
NASH (23)
Neurodegenerative disease (114)
Neuropsychiatric disorders (34)
Neuroscience (2106)
NextGen: Class of 2025 (7637)
Non-profit (5082)
Now hiring (40)
Obesity (423)
Opinion (275)
Ovarian cancer (78)
Pain (99)
Pancreatic cancer (86)
Parkinson's disease (160)
Partnered (22)
Patents (250)
Patient recruitment (116)
Peanut (51)
People (64182)
Pharmaceutical (132)
Pharmacy benefit managers (21)
Phase I (22287)
Phase II (31454)
Phase III (23744)
Pipeline (1255)
Policy (170)
Postmarket research (3281)
Preclinical (9882)
Press Release (72)
Prostate cancer (113)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (430)
Real estate (7167)
Recruiting (75)
Regulatory (26093)
Reports (57)
Research institute (2655)
Resumes & cover letters (589)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (81)
Series A (143)
Series B (91)
Service/supplier (27)
Sickle cell disease (58)
Special edition (18)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4195)
State (2)
Stomach cancer (16)
Supply chain (76)
Tariffs (45)
The Weekly (80)
Vaccines (812)
Venture capitalists (44)
Weight loss (304)
Women's health (38)
Worklife (20)
Date
Today (213)
Last 7 days (949)
Last 30 days (2846)
Last 365 days (35395)
2025 (11549)
2024 (37916)
2023 (42567)
2022 (53927)
2021 (58722)
2020 (57665)
2019 (51316)
2018 (39098)
2017 (36857)
2016 (37803)
2015 (43829)
2014 (38601)
2013 (34721)
2012 (36582)
2011 (36633)
2010 (36207)
Location
Africa (1199)
Alabama (60)
Alaska (7)
Arizona (248)
Arkansas (14)
Asia (48778)
Australia (8390)
California (6429)
Canada (2057)
China (563)
Colorado (284)
Connecticut (301)
Delaware (158)
Europe (110497)
Florida (941)
Georgia (220)
Hawaii (1)
Idaho (63)
Illinois (616)
India (30)
Indiana (331)
Iowa (12)
Japan (169)
Kansas (110)
Kentucky (28)
Louisiana (14)
Maine (70)
Maryland (968)
Massachusetts (4940)
Michigan (246)
Minnesota (419)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (65)
New Hampshire (70)
New Jersey (1821)
New Mexico (31)
New York (1823)
North Carolina (1122)
North Dakota (9)
Northern California (2750)
Ohio (219)
Oklahoma (15)
Oregon (46)
Pennsylvania (1420)
Puerto Rico (13)
Rhode Island (36)
South America (1573)
South Carolina (24)
South Dakota (1)
Southern California (2380)
Tennessee (104)
Texas (955)
United States (24676)
Utah (191)
Virginia (169)
Washington D.C. (69)
Washington State (600)
West Virginia (3)
Wisconsin (68)
820,225 Results for "mitsui and co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.
March 3, 2025
·
5 min read
Pharm Country
Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific
Lokavant , the clinical trial intelligence platform company, today announces an $8 million strategic investment from global business titan Mitsui & Co. Ltd. to expand its AI-optimized platform across the Asia-Pacific (APAC) region.
October 3, 2023
·
3 min read
Business
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., and Sumitomo Mitsui Banking Corporation announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company.
April 22, 2024
·
5 min read
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Press Releases
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
March 13, 2025
·
3 min read
Job Trends
Astellas Establishes Open Innovation Hub for Tumor Microenvironment Research with Cutting-Edge Spatial Biology, in Mitsui Fudosan’s “MITSUI LINK-Lab KASHIWA-NO-HA 1"
Astellas Pharma Inc. and Mitsui Fudosan Co., Ltd. announced that Astellas will establish a “TME imaging and interactive research for innovation " open innovation hub in October, 2023 in “MITSUI LINK-Lab KASHIWA-NO-HA 1" operated by Mitsui Fudosan.
June 29, 2023
·
6 min read
Press Releases
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments
April 28, 2025
·
10 min read
Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.
July 1, 2024
·
5 min read
Press Releases
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials
October 8, 2024
·
3 min read
Drug Development
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.
May 28, 2024
·
2 min read
1 of 82,023
Next
